Hayan Yoon, Ph.D.

Office

Silicon Valley

Practices

Patent Trial & Appeal Board (PTAB) Proceedings

Industries

Education & Admissions

J.D., Stanford Law School

Ph.D., Biochemistry
Harvard University

B.S., Molecular Biology
Seoul National University

Admitted to practice in California

Registered to practice before the U.S. Patent and Trademark Office

Hayan provides comprehensive patent guidance to her clients, specializing in advising emerging growth and publicly traded life science companies and venture capital firms on various aspects of strategic intellectual property and patent counseling.

Hayan has an in-depth grasp of the life sciences industry and corporate goals. She leverages her significant scientific and legal experience in life sciences to counsel clients related to U.S. and foreign patent prosecution and management, patent strategy, IP diligence pre-litigation assessment, post-issuance proceeding, and validity and infringement opinions. She has extensive experience in assessing competitive IP landscapes and complex IP assets and advising strategies for improving IP assets while mitigating risks.

Before her legal career, Hayan was a postdoctoral fellow at UC Berkeley and the Damon Runyon Cancer Research Foundation, and a researcher at a gene therapy company. She maintains her passion for life sciences while providing counsel to her clients in the life science industry.

Hayan's representative experience includes IP diligence in the following deals:

Royalty Pharma on IP diligence in its $525 million purchase of royalties for ImmuNext's frexalimab
Pharmakon’s non-dilutive term loan financing for ImmunoGen for up to $175M
Pharmakon’s $100 million loan agreement with Immunocore
Passage Bio’s $110 million series B financing and initial and follow-on public offerings
Impel Pharmaceuticals’ sale to JN BIDCO LLC
Adaptive Biotechnologies’ $345 initial public offering

Hayan's representative experience includes IP diligence in the following deals:

Royalty Pharma on IP diligence in its $525 million purchase of royalties for ImmuNext's frexalimab
Pharmakon’s non-dilutive term loan financing for ImmunoGen for up to $175M
Pharmakon’s $100 million loan agreement with Immunocore
Passage Bio’s $110 million series B financing and initial and follow-on public offerings
Impel Pharmaceuticals’ sale to JN BIDCO LLC
Adaptive Biotechnologies’ $345 initial public offering

Practices